Microbiology Society; Bron
https://microbiologysociety.org/22 juni 2020
An interview with Professor Jinyu Shan; Bron
https://microbiologysociety.org/members ... -shan.htmlProfessor Jinyu Shan is a Research Fellow at Phelix Research and Development and the Chief Scientific Officer at the University of Leicester, UK. He is a member of the Microbiology Society and, in this interview, he tells us about how he is using his expertise in phage to develop novel diagnostics to treat Lyme disease.
Tell us more about your role and area of research
I am a Research Fellow funded by the charity Phelix Research and Development. We aim to address the lack of a sensitive diagnostic for Lyme disease and co-infections. We adopt a novel approach, based on my previous expertise in phage (viruses associated with the bacterial genomes) biology and ecology, and take advantage of the fact that most pathogenic bacteria, carry on average, two to six complete or partial temperate phages.
These sequences form the bases of a template, to which real time polymerase chain reaction (qPCR) primers and probes can be designed. We have previously revealed a tight correlation between phages and Lyme bacteria, and successfully developed and validated a qPCR assay for the diagnosis of Lyme disease. We have shown, on patient samples, that this phage-based qPCR is six times as sensitive as the standard serological test. Ongoing and future research will focus on Lyme co-infections, including relapsing fever and Bartonella infection.
Why is your research important?
Doctors find it extremely difficult to help Lyme disease patients, due to a lack of reliable and sensitive diagnostic methods to detect and distinguish Borrelia from co-infections. This lack of effective laboratory diagnostics results in empirical decision-making and antibiotic misuse/overuse. There is, thus, an urgent need for novel diagnostics that could offer sensitive diagnosis to guide clinicians to treat patients with appropriate antibiotics accordingly.
Interessante visie over antibiotica. In de praktijk krijgen patiënten bij de Lyme arts, Ilads werkend, op basis van positieve uitslagen van LTT testen langdurige antibiotica behandelingen en of in combinatie met natuurlijke middelen voorgeschreven. Bij positieve uitslagen op Borrelia en of B. miyamotoi met de Phelix Phage Borrelia test wordt door de Lyme arts, Ilads werkend, Disulfiram aan de behandelingen toegevoegd; Bron
https://www.healthrising.org/blog/2020/ ... eriophage/ me/cvs patiënten met negatieve LTT testen en niet-gediagnosticeerde patiënten blijken (toch) Borrelia en of B. miyamotoi te hebben?
Dat heb ik eerder gehoord in 2014. Het Nederlandse en het Belgische Parlement zijn toegesproken door verschillende Lyme artsen; Bron
https://nelelijnen.be/index.php/lyme/30 ... april-2014 en Ronde Tafel - De strijd tegen de Ziekte van Lyme - deel 2; Bron
https://www.youtube.com/watch?v=ZGlejdfH31s De LTT testen werden toen aangeprezen. De andere testen van Red Laboratories werden besproken. In die tijd testten veel patiënten met een test PCR with sequencing ('speciale' test only in België..(?)) positief op Bartonella (en verschillende species) en kregen de patiënten de diagnose chronische Bartonella. Rondom Bartonella is het stilletjes geworden. En de Phelix Phage test kan nog geen Bartonella detecteren.